Structure Therapeutics Posts $1.98/Share Q3 Loss, Nearly Triple the 58-Cent Consensus
GPCR is trading near its 52-week low of $18.7 (12% above the low).
Summary
Structure Therapeutics reported a Q3 adjusted loss of $1.98 per share, far wider than the 58-cent loss fifteen analysts expected and outside the -$1.37 to -$0.36 range. The net loss was $144.76 million with zero revenue, as Phase 3 spending ramps. That follows the 8-K and 10-Q filed November 9, which disclosed the same $144.8M loss and $1.2B in cash said to fund operations through 2028 — so the balance sheet is not the issue; the burn rate is. The stock has already fallen 30.5% this quarter and 68.8% this year, and the consensus loss estimate was cut about 14.2% over the last three months. The Street still carries a buy rating (16 buy, 1 hold) and a $100 median price target, which now sits far above the $21.73 last close.
At the time of this announcement, GPCR was trading at $20.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $18.70 to $94.90. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.